Institute Professor, The Koch Institute for Integrative Cancer Research, MIT; former Director, McGovern Institute for Brain Research; Nobel Laureate; founder of Biogen, Inc. (now Biogen Idec, Inc.) and Alnylam; National Academy of Sciences.
Director of the Center for Assessment Technology and Continuous Health (CATCH) and Physician‐in‐Chief Emeritus at Massachusetts General Hospital; Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School.
Member of the Whitehead Institute for Biomedical Research and Professor of Biology at MIT, Investigator of the Howard Hughes Medical Institute, noted RNA and RNAi expert, and a founder of Alnylam.
NANCY J. BROWN,
Dean of the Yale School of Medicine and Professor of Internal Medicine; former Chair of Medicine and Physician-in-Chief of Vanderbilt University Hospital; National Academy of Medicine; Member, American Society of Clinical Investigation; Master, American College of Physician.
PRIYA S. KISHNANI,
C.L. and Su Chen Professor of Pediatrics, Medical Director, YT and Alice Chen Pediatrics Genetics and Genomics Center, Division Chief, Medical Genetics and Professor of Molecular Genetics and Microbiology, Duke University Medical Center.
MUTHIAH (MANO) MANOHARAN,
Senior Vice President, Innovation Chemistry and Distinguished Scientist at Alnylam; world-leading nucleic acid and bioconjugate chemist; author of more than 200 publications and over 300 abstracts, as well as the inventor of over 180 issued US patents.
JOHN M. MARAGANORE,
Founding Chief Executive Officer of Alnylam (2002-2021); Venture Partner at ARCH Venture Partners; Member of the Board of Directors of Agios Pharmaceuticals; Member and former Chair of the Biotechnology Industry Organization (BIO); Mentor and Member of the Board of Directors of The Termeer Foundation.
Entrpreneur-in-Residence at Third Rock Ventures; former Head of Research at Alnylam; member, Scientific Advisory Board, Editas Medicine.
DANIEL J. RADER,
Professor of Medicine and Chief, Division of Translational Medicine and Human Genetics, at the Perelman School of Medicine at the University of Pennsylvania.
Hahn Professor of Molecular Biology and Chemistry at Scripps Research Institute; National Academy of Sciences, American Academy of Arts and Sciences, and Institute of Medicine member; co-founder of Cubist, Alkermes; and Repligen, and a founder and member of the Board of Directors of Alnylam.
Professor for Metabolic Diseases at the Institute of Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) in Zurich.
Chief Innovation Officer, Alnylam; Past President, EVP R&D, Alnylam; Fellow of the Royal College of Physicians; Member of the Board of Directors for Editas Medicine Inc. and Scholar Rock Inc. Former member of the Board of Visterra, Inc.